Targeting metabolic syndrome

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1203-1206

  Fong, Tung M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Diabetes; Dyslipidaemia; Hypertension; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; AMG 331; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ A RECEPTOR; DIPEPTIDYL PEPTIDASE IV; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GR 265261 X; GSK 876169; MELANIN CONCENTRATING HORMONE; MELANOCORTIN 4 RECEPTOR; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; NEUROPEPTIDE Y; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RIMONABANT; SIBUTRAMINE; SITAGLIPTIN; SR 141716 A; TOPIRAMATE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZONISAMIDE;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

ANIMALS; CALLITHRIX; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FRUCTOSE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MACACA MULATTA; METABOLIC SYNDROME X; MICE; OBESITY; WEIGHT LOSS;

EID: 4544247230     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1203     Document Type: Conference Paper

References (11)

1. GRUNDY SM, BREWER HBJ, CLEEMAN JI et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 109:433-438.
2. JAMES WPT: Appropriate Asian body mass indices? Obesity Rev. (2002) 3:139.
3. WILLIAMSON DF, PAMUK E, THUN M et al.: Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40 - 64 years Am. J. Epidemiol. (1995) 141:1128-1141.
4. SJOSTROM CD, LISSNER L, WEDEL H, SJOSTROM L: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes. Res. (1999) 7:477-484.
5. REAVEN G, SEGAL K, HAUPTMAN J, BOLDRIN M, LUCAS C: Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am. J. Cardiol. (2001) 87:827-831.
6. MOLLER DM, KAUFMAN KD: Metabolic syndrome - a clinical and molecular perspective. Ann. Rev. Med. (2004) (In Press).
7. OLIVER WRJ, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98:5306-5311.
8. PRATLEY R, GALBREATH E. Twelve-week monotherapy with the DPP-4 inhibitor LAF-237 improves glycemic control in patients with Type 2 diabetes. American Diabetes Association 64th Annual Scientific Sessions. Florida USA (2004) 355-OR.
9. HERMAN GA, ZHAO P-L, DIETRICH B et al.: The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in Type 2 diabetics. American Diabetes Association 64th Annual cientific Sessions. Florida, USA (2004) 353-OR.
10. BREWER HB Jr: High density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Artherioscler. Thromb. Vasc. Biol. (2004) 24:387-391.
11. GANTZ I, FONG TM: The melanocortin systems. Am. J. Physiol. (2003). 284:E468-E474.